ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS

Información del proyecto

UNITE4TB

Identificador del acuerdo de subvención: 101007873

DOI 10.3030/101007873

Fecha de la firma de la CE 29 Junio 2021

Fecha de inicio 1 Junio 2021

Fecha de finalización 31 Mayo 2028

Financiado con arreglo a

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coste total € 185 000 000,00

Aportación de la UE € 92 500 000,00

Coordinado por

STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM
Netherlands

Resultado final

Documents, reports (6)

Report of kick-off meeting

Report of kickoff meeting

Communication and dissemination plan
Establish CAG
Establish SAB and RAB
Report of first annual consortium meeting
Establish EAB

Other (2)

Inaugural meeting with communication professionals of the partners in the consortium
Establish Young Investigators Group

Websites, patent fillings, videos etc. (1)

Visual identity and communication toolkit, including project website

Visual identity and communication toolkit including project website

Publicaciones

Peer reviewed articles (5)

Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin

Autores: Keutzer L, You H, Farnoud A, Nyberg J, Wicha SG, Maher-Edwards G, Vlasakakis G, Moghaddam GK, Svensson EM, Menden MP, Simonsson USH, On Behalf Of The UNITE4TB Consortium
Publicado en: Pharmaceutics, 2022, ISSN 1999-4923
Editor: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics14081530

Tuberculosis: current challenges and beyond

Autores: Raquel Villar-Hernández, Arash Ghodousi, Olha Konstantynovska, Raquel Duarte, Christoph Lange, Mario Raviglione on behalf of the UNITE4TB Consortium
Publicado en: Breath, 2023, ISSN 2073-4735
Editor: European Respiratory Society
DOI: 10.1183/20734735.0166-2022

Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies

Autores: Heyckendorf J, Georghiou SB, Frahm N, Heinrich N, Kontsevaya I, Reimann M, Holtzman D, Imperial M, Cirillo DM, Gillespie SH, Ruhwald M, Consortium UNITE4TB
Publicado en: Clinical Microbiology Reviews, Edición 21 March 2022, 2022, Página(s) n/a, ISSN 1098-6618
Editor: American Society for Microbiology
DOI: 10.1128/cmr.00227-21

Implementing molecular tuberculosis diagnostic methods in limited-resource and high-burden countries

Autores: Anca Vasiliu, Antonia Morita Iswari Saktiawati, Raquel Duarte, Christoph Lange, Daniela Maria Cirillo on behalf of the UNITE4TB Consortium
Publicado en: Breath, 2023, ISSN 2073-4735
Editor: European Respiratory Society
DOI: 10.1183/20734735.0226-2022

Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development

Autores: Mockeliunas L, Faraj A, van Wijk RC, Upton CM, van den Hoogen G, Diacon AH, Simonsson USH
Publicado en: Front. Pharmacol., 2023, ISSN 1663-9812
Editor: Frontiers Media S.A.
DOI: 10.3389/fphar.2023.1150243

Non-peer reviewed articles (1)

UNITE4TB: a new consortium for clinical drug and regimen development for TB

Autores: Boeree, M. J.; Lange, C.; Thwaites, G; Paton, N ; de Vrueh, R.; Barros, D.; Hoelscher, M.; on behalf of the UNITE4TB Consortium
Publicado en: International Union Against Tuberculosis and Lung Disease, Edición Volume 25, Number 11, 1 November 2021, 2021, Página(s) 886-889, ISSN 1027-3719
Editor: International Union Against Tuberculosis And Lung Disease/Union Internationale Contre la Tuberculose et les Maladies Respiratories
DOI: 10.5588/ijtld.21.0515